Establishment Labs (ESTA) Scheduled to Post Earnings on Wednesday

Establishment Labs (NASDAQ:ESTA) is set to issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Establishment Labs has set its FY 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Wednesday, February 28th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.16. Establishment Labs had a negative net margin of 47.53% and a negative return on equity of 357.81%. The company had revenue of $31.60 million during the quarter, compared to analysts’ expectations of $31.44 million. During the same period last year, the company posted ($0.55) earnings per share. Establishment Labs’s quarterly revenue was down 27.9% on a year-over-year basis. On average, analysts expect Establishment Labs to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $50.01 on Wednesday. Establishment Labs has a 52 week low of $16.96 and a 52 week high of $73.00. The firm has a fifty day simple moving average of $48.57 and a two-hundred day simple moving average of $36.75. The company has a debt-to-equity ratio of 10.26, a current ratio of 3.06 and a quick ratio of 1.67.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Citigroup lifted their price objective on shares of Establishment Labs from $49.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Establishment Labs from $46.00 to $53.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Mizuho lifted their price objective on shares of Establishment Labs from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Finally, Stephens reissued an “overweight” rating and issued a $47.00 price objective on shares of Establishment Labs in a research note on Thursday, January 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $55.00.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.